Eli Lilly diabetes drug wins FDA approval to lower cardiovascular risks - Heart disease is is the leading cause of death for ...

This shot could help to give you a health edge in more ways than one.

Roivant's autoimmune drug approval, Cytokinetics reports full data for heart condition treatment, and more biotech news ...

On Aug. 28, the U.S. Food and Drug Administration (FDA) approved Mounjaro to lower the risk of heart events, including heart ...

AstraZeneca detailed the surprise failure of a closely watched heart disease trial, a study with ripple effects for a ...

Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for ...

Researchers say studying their children could help investigate the genetic and environmental factors that contribute to a ...

David Beard /For t Vinay Badhwar, Executive Chief of HVI, speaks during a 10th anniversary ceremony for the WVU Heart & Vascular Institute on Friday. David Beard /For the ...

Gene editing reduced cholesterol by about 50% in an extremely small sample of patients over a year of follow-up, according to ...

Research shows this tirzepatide GLP-1/GIP medication may help prevent cardiovascular emergencies in high-risk type 2 diabetes ...

With the approval, Eli Lilly’s Mounjaro becomes the first dual GIP/GLP-1 receptor agonist indicated to lower the risk of ...